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OBJECTIVES: Intraductal papillary mucinous neoplasms (IPMNs) are associated with risk of pancreatic ductal
adenocarcinoma (PDAC). It is unclear if an IPMN in individuals at high risk of PDAC should be
considered as a positive screening result or as an incidental finding. Stratified familial pancreatic
cancer (FPC) populations were used to determine if IPMN risk is linked to familial risk of PDAC.
METHODS: This is a cohort study of 321 individuals from 258 kindreds suspected of being FPC and undergoing
secondary screening for PDAC through the European Registry of Hereditary Pancreatitis and Familial
Pancreatic Cancer (EUROPAC). Computerised tomography, endoscopic ultrasound of the pancreas and
magnetic resonance imaging were used. The risk of being a carrier of a dominantmutation predisposing
to pancreatic cancer was stratified into three even categories (low, medium and high) based on:
Mendelian probability, the number of PDAC cases and the number of people at risk in a kindred.
RESULTS: There was amedian (interquartile range (IQR)) follow-up of 2 (0–5) years and amedian (IQR) number of
investigations per participant of 4 (2–6). One PDAC, two low-grade neuroendocrine tumours and 41
cystic lesions were identified, including 23 IPMN (22 branch-duct (BD)). The PDAC case occurred in
the top 10% of risk, and the BD-IPMN cases were evenly distributed amongst risk categories: low
(6/107), medium (10/107) and high (6/107) (P5 0.63).
CONCLUSIONS: The risk of findingBD-IPMNwas independent of genetic predisposition and so they should bemanaged
according to guidelines for incidental finding of IPMN.
Am J Gastroenterol 2019;114:155–164. https://doi.org/10.1038/s41395-018-0395-y
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is usually detected
too late for curative treatment, and in 80% of patients surgical
resection is not possible at the time of diagnosis (1). Of those who
undergo surgery and adjuvant chemotherapy, only 20–30% can
expect to survive 5 years (2–4). The best survival can be achieved if
tumours are small at the time of resection, but such tumours are
rarely found (5). Ideally, pre-cancerous lesions could be removed
before they progress. PDAC is generally accepted to arise from
pancreatic intraepithelial neoplasms (PanINs), and these mi-
croscopic lesions are graded from 1 to 3, with 3 being equivalent
to carcinoma in situ. However, even PanIN3 are diﬃcult or im-
possible to identify by imaging. Intraductal papillary mucinous
neoplasms (IPMNs) can be detected by pancreatic imaging. There
is some controversy over whether IPMNs develop into PDAC,
with invasive IPMN being a separate form of malignancy with
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a better prognosis (6). PDAC do develop in patients with IPMN,
sometimes after the IPMNs have been successfully resected (7),
suggesting association of IPMN and cancer that goes beyond
simple progression. Branch-duct (BD) IPMNs are found in at
least 5% of the general population and lead to invasive cancer in
a very small proportion of cases (8); this risk is very much higher
in main-duct (MD) IPMNs (9). Mixed-type IPMNs carry a sim-
ilar risk of invasive carcinoma as MD-IPMN (around 45%) (10).
Guidelines on management of IPMNs were produced in
Sendai in 2006, with reﬁnement in the Fukuoka guidelines (2012
and 2016), in essence suggesting surveillance of BD-IPMN and
possible resection of MD-IPMN. The American Gastroentero-
logical Association introduced guidelines to limit the length of
surveillance of BD-IPMN; this remains controversial but enforces
the idea of BD-IPMN as lesions that can usually be safely left in
situ. A European guideline document has also been published,
again recommending a conservative approach to managing BD-
IPMN, but of not stratifying the risk of progression according to
(amongst other factors) familial history of pancreatic cancer (11).
Screening for pancreatic cancer requires a highly enriched pop-
ulation with a high prevalence of PDAC; at present, the only
accepted screening populations are those with autosomal domi-
nant predisposition for pancreatic cancer (12). Identifying a BD-
IPMN during screening raises the question of whether the lesion
should be managed according to standard guidelines or whether
this represents a consequence of the genetic predisposition for
cancer and so could merit immediate resection.
The International Cancer of the Pancreas Screening (CAPS)
consortium has deﬁned potentially relevant ﬁndings in screening
as early PDAC (T1N0M0R0), grade 3 PanIN, and high grade BD
or MD IPMN (13). We have reviewed 21 screening reports
(14–34); in total, 30 pancreatic cancers and 2 pancreatic neuro-
endocrine tumours were reported. However, the most common
positive ﬁndings were cystic lesions, including 6MD-IPMNs and
60 BD-IPMNs. Of the 1780 individuals who were screened, 131
underwent surgical resection due to what was considered to be
a positive ﬁnding.
The European Registry of Hereditary Pancreatitis and Fa-
milial Pancreatic Cancer (EUROPAC) was established in 1997.
EUROPAC recruits families with either hereditary pancreatitis or
familial pancreatic cancer (FPC) and oﬀers cancer screening on
a research basis. This work only deals with screening in FPC. In
the majority of FPC families no known causative mutation has
been identiﬁed and DNA sequencing cannot be used to distin-
guish families with genuine autosomal dominant predisposition
from families where the cancer cluster occurs by chance or due to
a polygenic predisposition. Estimates of relative risk of PDAC
vary between 6- and 120-fold depending on the nature of family
selection (35,36), the 120-fold level being most consistent with
autosomal dominant predisposition and lower values perhaps
indicating a higher proportion of random clusters which will not
give adequate elevated prospective risk for screening.
This paper describes the results from EUROPAC pilot
screening study. A PDAC case and anMD-IPMNwere identiﬁed
along with two low-grade neuroendocrine tumours, but the most
frequent ﬁndings were cystic lesions, the most common of which
were BD-IPMNs. If BD-IPMNs can genuinely be considered
a positive ﬁnding in screening, then it would be logical to assume
that they should be more frequently encountered in individuals
with the highest risk of pancreatic cancer as a result of autosomal
dominant predisposition. We have assessed if familial risk (as
opposed to risk due to other factors such as age or smoking)
correlates with a higher incidence of IPMNs in our FPC kindreds.
MATERIALS AND METHODS
Patients and ethics
EUROPAC is administered from Liverpool in the United King-
dom, Greifswald in Germany and Clichy in France, mainly
recruiting from Western Europe. It is a patient-led registry
(ethical approvals MREC 03/8/069 and 07/H1211/96). Screening
inclusion depended on at least two ﬁrst-degree relatives with
conﬁrmed PDAC or a high-risk mutation. In some of the
EUROPAC families, a known causative mutation has been
identiﬁed (mutations in BRCA2, CDKN2a, STK11 or mismatch
repair genes). These are associated with autosomal dominant
predisposition that can be conﬁrmed by segregation of the mu-
tation with cancer cases. However, in most of our families DNA
sequencing has not been possible in enough cases to conﬁrm
segregation, so we cannot rule out low penetrance in some of our
families despite the presence of known causative mutations in
screened individuals (e.g., a BRCA2 mutation cannot be guar-
anteed to equate to very high risk because the individualmay have
a protective genetic background not seen in high-risk families
with BRCA2). All screened individuals had to be aged over 40
years or 10 years younger than the youngest aﬀected ﬁrst-degree
relative.
Epidemiological data were collected via questionnaires sup-
ported by clinical consultations and stored on a database (Prog-
eny version 8.01) in accordance with the UK Data Protection Act
(1998). Matched DNA was kept under the care of the Merseyside
and Cheshire Genetics Service. Recruitment for screening was
patient led, with approximately 40% uptake.
Screening protocol
Baseline measurements of serum glucose and Ca19-9 were per-
formed alongside imaging (both pancreas protocol computed
tomography and endoscopic ultrasound of the pancreas). The
screening process is summarised in Fig. 1. Consenting individuals
had collection of duodenal juice, with secretin stimulation. If the
juice contained no cancer-associated genetic abnormalities, par-
ticipants entered a 3-yearly screening cycle, with staggered en-
doscopic ultrasound (EUS) and/or magnetic resonance imaging.
In patients without juice collection or with cancer-associated
mutations in their juice, there was an annual pathway consisting
of repeat blood testing and EUS. Abnormalities were discussed at
the supra-regional pancreatic multi-disciplinary team meeting.
Molecular analysis of duodenal juice
Extracted DNA from juice was quantiﬁed by real-time PCR for
a speciﬁc genomic DNA sequence (KRAS). The methodology for
molecular analysis has been previously described (37): a yeast
functional assay was used to identify p53 mutations, Ampliﬁca-
tion Refractory Mutation System was employed for analysis of
KRASmutations and a real-time methylation-speciﬁc PCR assay
for CDKN2a promoter methylation. For later analysis, deep se-
quencing of Tp53 was carried out on juice samples using an Ion
Torrent Personal Genome Machine. Libraries were constructed
as described in manufacturer’s protocols (38), and in order to
avoid false positive results fromPCRerror, the templateDNAwas
diluted to 10 genomes per reaction prior to making each library.
Minimum allele frequency for a genuine mutation would there-
fore be approximately 10, and a 1%mutation rate would be 1 out









of 10 libraries from the same patient with a mutant allele fre-
quency of 10% and the rest wild type.
Risk calculation
Thepurpose of this studywas to evaluate the relationship between
screening results and familial predisposition, and risk was
therefore only evaluated in terms of family structure. Other fac-
tors, such as age and smoking that increase risk of cancer but may
also increase risk of cystic lesions, were not included. The concept
of family index (FI) was used, whereby the number of cases of
PDAC in each family was taken as the numerator and the square
root of the number of at risk individuals as the denominator. To
allow for no individuals of 40 or above, one was added to the
number at risk.
FI ¼ Number  of   affected  individuals
√½ðNumber  of   individuals  in  kindred$ 40  yearsÞ1 ð1Þ:
Mendelian principles were used to calculate the chance of
inheriting a high-risk allele. For example, any ﬁrst-degree relative
of a pancreatic cancer case has a 50% chance of being a mutation
carrier, reducing to 25% in a nephew or niece. If a potential
causative mutation was identiﬁed the chance was considered as
100%. FI was multiplied by percentage chance of inheritance to
give an arbitrary score for risk (e.g., an individual in a family with
FI5 0.5 and a 50% chance of being a carrier has a risk score of 25).
The arbitrary risk score calculated was compared in pro-
spective cancer cases on the registry to a division of families based
simply on number of cases and number of generations aﬀected.
Statistical analysis
Continuous variables are presented as median with interquartile
range (IQR). Risk groups were created pragmatically based on ter-
tiles of thewhole screened population, giving low,mediumandhigh
risk. The numbers of each ﬁnding in each tertile were compared
using Pearson’s chi square or Fisher’s exact testing as appropriate.
RESULTS
The demographics of all individuals consented and recruited to
the FPCEUROPAC registry are described inTable 1. The families
are split according to number of pancreatic cancer cases and
generations aﬀected.
In Table 2 all families that would have included individuals
(registered or unregistered relatives) eligible for screening in the
year 2000 are shown, broken down by family type as in Table 1.
The number of prospective cancers (i.e., cancers occurring after
2000 and before October 2016) is given, conﬁrming the high risk
of cancer in this cohort.
The prospective cancer cases are described in Table 3. There
was a trend for the prospective cases to have slightly older age of
cancer onset than the historical cases and this trendwas seen in all
categories of family. The median arbitrary risk score for all pro-
spective cancer cases was 40, with the highest values in families
with more cases of cancer (e.g., 3 cases in more than one gener-
ation having a median risk score of 50). Seventy-ﬁve percent of
prospective pancreatic cancer cases had an arbitrary risk score at
diagnosis of greater than 31.
Figure 1 shows the EUROPAC protocol for screeningmembers
of FPC kindreds. As of October 2016, there were 3031 individuals
who would be eligible for secondary screening; however, only 791
of these were registered. These 791 patients were informed of their
eligibility and from this point onwards, uptake of screening was
entirely patient led. The team did not approach patients beyond
informing them of their eligibility for screening.
EUROPAC had recruited 321 individuals for screening from
cancer families up to October 2016 (321/3031 10.6% of all eligible
individuals). In all, 123 participants had completed more than
Fig. 1 EUROPAC screening protocol. There is a 3-yearly screening cycle following a baseline assessment consisting of computed tomography (CT),
endoscopic ultrasound (EUS) and blood tests. There is EUS imaging at the end of each cycle, followed by collection of pancreatic juice (previously this was
done by cannulation of the pancreatic duct, currently by collection from the duodenum following secretin stimulation) and molecular analysis the year
after. in patients who do not have juice collection or who had a cancer-associatedmutation in their duodenal juice, there is an annual pathway consisting
of repeat blood testing and EUS/magnetic resonance imaging (MRI). Any abnormalities identified in imaging or molecular tests are discussed at the
supra-regional pancreatic multi-disciplinary team (MDT) meeting. The MDT may recommend further clinical investigations, surgery or whether the
participant undergoes annual surveillance or regular clinical review and/or follow-up
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two screening cycles, 46 had completed two cycles, 71 one cycle
and 11 had a ﬁnding on baseline screening investigations, giving
a total of 786 screening cycles completed. In addition, there were
70 individuals who had been recruited and undergone baseline
screening but with less than 1 year of follow-up and with no
abnormal ﬁndings. The median screening follow-up was 2 years
(IQR0–5) and themedian number of screening investigations per
participant was 4 (IQR 2–6).





































































































EUROPAC European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer, F female, FAMMM familial atypical multiple mole melanoma, FPC familial
pancreatic cancer, HNPCC hereditary non-polyposis colorectal cancer (Lynch Syndrome), M male, PDAC pancreatic ductal adenocarcinoma, PJS Peutz Jegher’s
syndrome
a Four individuals were recruited for screening from a family with a CDKN2a mutation but were later found to not be carriers
b Four individuals with MLH1 mutations and 4 defined on family history alone
c Families with cancer syndromes (none with known causative mutations)









Table 3 Prospective cancer cases between 2000 and 2016 showing the range of familial risk
New cancer cases (2000–2016) Median FI at
diagnosis (IQR)
Median risk score at














































0.7 (0.6–0.8) 37.8 (32.0–40.8)








0.8 (0.6–1.0) 40.0 (31.6–50.0)
FI family index, IQR interquartile range
Table 2 Individuals in EUROPAC kindreds followed from 2000 to 2016 showing prospective cancers to demonstrate high risk











































































































EUROPAC European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer, IQR interquartile range
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The ﬁndings from screening are summarised in Table 4 and
Fig. 2. The most common ﬁndings were cystic lesions: 41 cystic
lesions were identiﬁed, of which 1 was a main-duct IPMN and 22
were branch-duct IPMNs. The other cystic lesions were too small
for deﬁnitive radiological classiﬁcation; although these may have
been very small branch-duct IPMN, it does rule out larger lesions
such as mucinous cystic neoplasias. Two pancreatic neuroendo-
crine tumours (pNETs) were discovered, both were resected and
were found to bewell diﬀerentiated. One PDACwas identiﬁed. In
addition, a gastrointestinal stromal tumour was discovered in the
stomach of one patient. Three pancreatic resections were per-
formed: for both pNETs and for the MD-IPMN. Histological
examination of the specimen from the MD-IPMN revealed
low-grade dysplasia ofmain lesion and also revealed an incidental
branch-duct IPMN with low-grade dysplasia. The one PDAC
case identiﬁed was unfortunately advanced at the time of di-
agnosis and was therefore inoperable. Within the screening co-
hort, there were four deaths from all causes; one being the
advanced PDAC, two from extra-pancreatic malignancy and one
cardiac-related death.
The most frequently used screening modality was EUS.
Computed tomography (CT) scan was only performed as part of
baseline investigation, unless clinically indicated due to positive
ﬁndings in other modalities. Magnetic resonance imaging (MRI)
was only routinely introduced into the screening protocol from
2014.
Of the 35 screened individuals with a known causative mu-
tation, only 2 had a signiﬁcant ﬁnding on screening; 1 out of 22
with a BRCA2 mutation had a 10 mm BD-IPMN that regressed
during clinical follow-up, and 1 out of 5 individuals with
a CDKN2a mutation had an 11 mm BD-IPMN which has
remained stable after 36 months of follow-up.
Only 48 participants consented for endoscopic retrograde
cholangiopancreatography with molecular analysis of pancreatic
juice and only 4 patients had positive molecular test results in at
least two analyses. This is too small a group to make any signif-
icant conclusions. Two of these patients had cystic lesions that
were too small for further characterisation. Both of the remaining
participants with two positive tests had EUS ﬁndings consistent
with minimal change chronic pancreatitis (although neither had
symptoms or diagnosis of pancreatitis and the imaging abnor-
malities resolved). The single PDAC case and one of the pNETs
did not undergo pancreatic juice molecular analysis. The other
pNET had undergone two separate pancreatic juice collections.
The ﬁrst gave wild-type KRAS and normal levels of CDKN2a
promoter methylation (0.01%), and Tp53 analysis failed. The
second test gave wild-type KRAS and Tp53, with CDKN2a anal-
ysis failing. TheMD-IPMN case did not undergo pancreatic juice
analysis in the screening cycle where the lesionwas identiﬁed, and
in a previous analysis they had wild-type KRAS and Tp53 with
normal CDKN2a promoter methylation (0.018%).
In Fig. 2 each screening event is shown with the outcome
colour coded, red for the cancer, pink for the pNETs, amber for
the mainduct IPMN, green for no signiﬁcant ﬁnding, etc. The
participants are ranked according to the risk score of the in-
dividual at the time of screening estimated as above. Four indi-
viduals were included for screening because of family history, but
were found not to have the disease mutation (a CDKN2a muta-
tion) identiﬁed subsequently in this family, and they therefore
were classiﬁed as having a zero elevated risk. The PDAC case was
identiﬁed in an individual who at the time of screening had 5 cases
of PDAC in the family and 17 individuals in the family tree over
the age of 40 years, giving an FI of 1.179. There was a 50% chance
of the individual being a carrier and so the risk score was 58.95.
This put the individual’s familial risk in the top 10% of risk scores
in the screened population.
Splitting the screening participants evenly into three groups
(low, medium and high) as shown in Fig. 2 indicated no corre-
lation between risk and incidence for branch-duct IPMN ( x2 5
0.937; P 5 0.632).
DISCUSSION
The screening described here was carried out under the as-
sumption of autosomal dominant predisposition for PDAC.
Table 4 Screening events stratified by risk group
Low risk Medium risk High risk
Median age (IQR):
whole group
58 (47–65) 52 (46–61) 53 (48–63)
Smoking: whole group
Yes 5 (4.7%) 11 (10.3%) 5 (4.7%)
No 56 (52.3%) 60 (56.1%) 65 (60.7%)
Ex 46 (43.0%) 36 (33.6%) 37 (34.6%)
PDAC 0 0 1
pNET 1 1 0
MD-IPMN 0 1 0
BD-IPMN 6 10 6
Size of BD-IPMN
3–5 mm 3 7 4
6–10 mm 1 3 2
.10 mm 2 0 0
Progression of BD-IPMN
Progressed 2 1 0
Stable 3 7 4
Regressed 1 2 2




60 (54–65) 52 (48–70) 59 (47–67)
Smoking: cystic lesion group
Yes 1 (9.1%) 2 (11.8%) 0
No 6 (54.5%) 9 (52.9%) 7 (53.8%)


















BD branch duct, IQR interquartile range, IPMN intraductal papillary mucinous
neoplasm, MD main duct, PDAC pancreatic ductal adenocarcinoma, pNET
pancreatic neuroendocrine tumour









Multigenic cancer predisposition will give heterogeneous risk
with only particular combinations of alleles passing a threshold
that would allow predictable development of malignancy, even if
all family members have some small elevated risk (39). The
combination of alleles responsible for speciﬁc cancer cases will be
unlikely to be seen again in the same family, so prospective risk
would be too low to justify cancer screening. Eﬀective screening
requires a single mutant gene that confers the bulk of risk, al-
though this may well be context speciﬁc (some genetic back-
grounds giving high penetrance and some low penetrance); in
such a situation family members who are noncarriers must be
assumed not to be at any elevated risk.
The probability of a cluster of PDAC without such pre-
disposition will increase with the number of at-risk individuals in
a kindred and will reduce with the number of pancreatic cancer
cases. Risk for an individual will depend on their age, exposure to
environmental risk factors and lifestyle, but none of these factors,
alone or in combination, would merit inclusion of an individual
in a screening programme, nor would they inﬂuence the pro-
spective risk of other family members.
A screening ﬁndingmust therefore be judged according to the
genetic risk of an individual. The one case of PDAC occurred
within the top 10% of familial risk and the one case ofMD-IPMN
was identiﬁed in a medium risk family. Twenty-two branch-duct
IPMNs were identiﬁed with equal probability in individuals of all
familial risk categories.
The 5-year follow-up of 367 individuals from the pop-
ulationbased Study of Health in Pomerania (SHIP) identiﬁed 48
participants who developed cystic lesions (12.9%). Although the
SHIP study is not directly comparable with the prospective
screening described here, it is notable that we identiﬁed a total of
41 cystic lesions in our population of 321 participants (12.8%),
and hence our data are entirely consistent with the expected
discovery of cystic lesions in the general population (40). Age is
a risk factor both for the development of pancreatic cancer and
IPMN (as shown in the SHIP analysis), and we deliberately did
not include age in our risk model, as the question was whether
genetic predisposition increased the risk of cystic lesions. Our
hypothesis was that the cystic lesions were intermediates in a ge-
netic predisposition for pancreatic cancer and could therefore be
taken as a positive result in a cancer screen. The cystic lesions
within the EUROPAC screening cohort were more common in
older participants, but this was true even for the low-risk group,
although very few prospective cancers occur in this group of
patients (see Table 3) and presumably many of the individuals in
this group were at no greater risk of pancreatic cancer than any
other individual of a similar age. The BD-IPMNs were also no
larger ormore likely to progress in the high-risk group than in the
low-risk group.
There is little doubt that BD-IPMNs are associated with cancer
risk. However, although an individual with a BD-IPMN may be at
greater risk of cancer, our data suggest individuals with a higher
inherited risk of PDAC are not at a higher risk of developing BD-
IPMN. Previously, Capurso et al. (41) showed that IPMNs were
more frequent in individuals with a familly history of pancreatic
cancer, and this was based on 21 IPMN cases (5.4 %) with a ﬁrst-
degree family history of PDAC compared to 6 controls (1.6 %), but
only 1 of thesewould have ﬁtted the criteria for FPCand this patient
still only had 1 ﬁrst-degree relative with PDAC (plus 2 second-
degree relatives). Our ﬁndings indicate that FPC is not associated
with greater predisposition for IPMN; genetic predisposition for
IPMNmay well be associated with higher risk of PDAC. Similarly,
patientswho smoke orwhohave diabetesmaywell bemore likely to
develop IPMN and be more likely to develop cancer.
The link between genetic predispostion to cancer and to
precursor lesions is complex, and syndromes such as familial
adenomatous polyposis predispose to cancer because they pre-
dispose to precursor lesions. These precursor lesions, albeit more
Fig. 2 Screening results stratified by risk that an individual carries a high penetrancemutation predisposing to pancreatic cancer. Riskwas estimatedbased
on number of cases of cancer, number of at-risk individuals in each family and the chance that a participant was carrying an autosomal dominant
determinant of cancer predisposition. Each individual is then represented by a coloured bar indicating the outcome of screening (as shown in the key).
Positive events are indicated with arrows and the tertiles of risk (along with the 10% upper risk group) are indicated by boxes below the x-axis
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commonly found, are not greatly more prone to progression than
similar lesions found in individuals without genetic pre-
disposition for cancer (42). In contrast, Lynch Syndrome (or
hereditary nonpolyposis colorectal cancer (HNPCC)) increases
the risk of precursor lesions progressing (43), and hence lesions
are less likely to be found but are much more worrisome if
identiﬁed. Naturally, if lesions are not related to the genetic
predisposition for cancer then they will neither be more frequent
normore aggressive. There is emerging support for an alternative
to the traditional progression model. A catastrophic process of
cancer development associated with Acinar Ductal Metaplasia
and lobular atrophy, independent of PanIN (44,45), ﬁts with
observations in familial pancreatic cancer (46). Atypical ﬂat
lesionsmay be positive screening results on the basis that they are
the pre-cancerous lesion typical for FPC (47), but unfortunately,
these cannot be identiﬁed without ﬁrst resecting the pancreas.
Thus, the EUROPAC study does not support the inclusion of
non-malignant pancreatic cystic lesions, including branch-duct
IPMNs, as positive ﬁndings on screening individuals from FPC
families.
The screening results presented here are consistent with the
outcomes described by other groups, with discovery of cystic
lesions far outweighing identiﬁcation of PDAC (14–34). The poor
return of screening programmes can be explained by inclusion of
too many low-risk individuals in the screening cohorts. Any
individual’s chance of being at high risk will be the same as the
chance of carrying a predisposing mutation (e.g., 50% for a ﬁrst-
degree relative). The actual risk will be lower because super-
imposed is the chance that the familymay just represent a random
cluster of cases. This means that most individuals undergoing
screening for PDAC on the sole basis of family history of the
disease have no elevated risk. No elevated risk of PDACmeans no
elevated risk of precursor lesions.
In 2007, Wang et al. (39) developed the PancPro Mendelian
model to identify high-risk individuals within FPC kindreds. In
our report we used a much simpler (pragmatic) risk score based
on the number of cases of pancreatic cancer in the family, which is
the most widely recognised measure of familial risk (35), with the
added advantage of stratifying risk within groups of families with
equal numbers of pancreatic cancer cases (see Table 3). Although
Table 3 shows that the prospective cancer cases have a higher FI
than equivalent individuals in our screened cohort, who have not
so far developed cancer, this cannot be considered as validation of
FI as a concept as in order to do this we would have to show
greater risk of cancer in a prospective cohort of individuals with
standardisation for all other risk factors (smoking, age, diabetes
etc.). We are carrying out such a prospective analysis with the
families shown in Table 1, but these data will not be available for
some years. This arbitrary risk score, although inferior to PancPro
in accuracy for quantifying PDAC risk, has the advantage for our
purpose that it avoids factors that would apply to sporadic pan-
creatic cancer and cystic lesions, such as age and smoking. In-
dependence of such risk factors was essential in showing that the
familial predisposition for cancer was largely (or entirely) in-
dependent of risk of developing BD-IPMN. The prospective
reporting of new cases of PDAC in individuals at higher familial
risk than those being screened indicates the need for a strategy to
encourage more high-risk individuals to participate in screening.
By restricting screening using PancPro (or equivalent) it should
be possible to focus resources on encouraging higher risk indi-
viduals to participate.
If we had identiﬁed an increased frequency of IPMN in
higher-risk individuals, we could have reasonably concluded that
FPC predisposes to the development of IPMN which in turn
predisposes to PDAC, but this was not the case. If we had found
that IPMNs encountered during screening progressed to PDAC,
we could have reasonably concluded that FPC increases the
probability of an IPMN progressing, but again this was not the
case. We cannot conclude from this work that IPMNs are an
intermediate stage in the development of PDAC within FPC
kindreds. IPMNs identiﬁed during screening should on this basis
be treated in the same way as IPMNs discovered incidentally in
the general population (according to the appropriate guidelines).
A desirable feature of risk stratiﬁcation is that it is unlikely to
increase the yield of branch-duct IPMNs.
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